Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RARA | P10276 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | LPL | P06858 | 1/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289254 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL11442846 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL1876486 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27414335 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15766204 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15174619 | 0.98 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL9812591 | 0.97 | RARB (0.58) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL31124111 | 0.95 | FOLH1 (0.58) | RARBPPARAPPARGFOLH1 | |
| SCHEMBL3387825 | 0.95 | FOLH1 (0.58) | RARBPPARAPPARGFOLH1 | |
| Phenol SCHEMBL28902755 | 0.92 | RARB (0.51) | RARBPPARAPPARGKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-8664423-B2 | Process for the preparation of acylated secondary alcohol alkoxylates and secondary alcohol alkoxylates | SHELL OIL COMPANY (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120196883-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2012-08-02 | — | — | US | disclosed |
| EP-2181763-B1 | Catalyst and process for alkoxylation | SHELL INT RESEARCH (NL) | 2012-06-20 | — | — | EP | disclosed |
| US-20120065310-A1 | COMPOSITION, COATED FILM FORMED OF THE COMPOSITION, LAYERED PRODUCT CONTAINING THE COATED FILM, AND ELECTRONIC DEVICE INCORPORATING THE LAYERED PRODUCT | ADACHI HIROAKI (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110237817-A1 | PROCESS FOR THE PREPARATION OF ACYLATED SECONDARY ALCOHOL ALKOXYLATES AND SECONDARY ALCOHOL ALKOXYLATES | SHELL OIL COMPANY | 2011-09-29 | — | — | US | disclosed |
| EP-2349974-A1 | PROCESS FOR THE PREPARATION OF ACYLATED SECONDARY ALCOHOL ALKOXYLATES AND SECONDARY ALCOHOL ALKOXYLATES | Shell Internationale Research Maatschappij B.V. (NL) | 2011-08-03 | — | — | EP | disclosed |
| US-20100167022-A1 | COMPOSITION, COATED FILM FORMED OF THE COMPOSITION, LAYERED PRODUCT CONTAINING THE COATED FILM, AND ELECTRONIC DEVICE INCORPORATING THE LAYERED PRODUCT | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2010049465-A1 | PROCESS FOR THE PREPARATION OF ACYLATED SECONDARY ALCOHOL ALKOXYLATES AND SECONDARY ALCOHOL ALKOXYLATES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2010-05-06 | — | — | WO | disclosed |
| EP-2181763-A1 | Catalyst and process for alkoxylation | Shell Internationale Research Maatschappij B.V. (NL) | 2010-05-05 | — | — | EP | disclosed |
| EP-2129665-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | CV Therapeutics Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008124532-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | CV THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RARB 975/4885MEN1 2199/4885ALDH1A1 4654/4885 |
| US-20110237817-A1 | PROCESS FOR THE PREPARATION OF ACYLATED SECONDARY ALCOHOL ALKOXYLATES AND SECONDARY ALCOHOL ALKOXYLATES | ADH1A, ADH1C, ADH5 | RARB 1733/4885MEN1 3923/4885ALDH1A1 47/4885 |
| US-20120196883-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | RARB 4776/4885MEN1 3263/4885ALDH1A1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.